Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Linear IgA Disease of the Gingiva Following Nivolumab Therapy.

Jonna S, Neiders M, Lakshmanan S, Khan A, DeKlotz T, Lanasa D, Gibney GT, Liu SV.

J Immunother. 2019 Nov/Dec;42(9):345-347. doi: 10.1097/CJI.0000000000000288.

PMID:
31246639
2.

The current state of molecular testing in the treatment of patients with solid tumors, 2019.

El-Deiry WS, Goldberg RM, Lenz HJ, Shields AF, Gibney GT, Tan AR, Brown J, Eisenberg B, Heath EI, Phuphanich S, Kim E, Brenner AJ, Marshall JL.

CA Cancer J Clin. 2019 Jul;69(4):305-343. doi: 10.3322/caac.21560. Epub 2019 May 22. Review.

3.

YAP/TAZ Inhibition Induces Metabolic and Signaling Rewiring Resulting in Targetable Vulnerabilities in NF2-Deficient Tumor Cells.

White SM, Avantaggiati ML, Nemazanyy I, Di Poto C, Yang Y, Pende M, Gibney GT, Ressom HW, Field J, Atkins MB, Yi C.

Dev Cell. 2019 May 6;49(3):425-443.e9. doi: 10.1016/j.devcel.2019.04.014.

PMID:
31063758
4.

Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma.

Gibney GT, Hamid O, Lutzky J, Olszanski AJ, Mitchell TC, Gajewski TF, Chmielowski B, Hanks BA, Zhao Y, Newton RC, Maleski J, Leopold L, Weber JS.

J Immunother Cancer. 2019 Mar 20;7(1):80. doi: 10.1186/s40425-019-0562-8.

5.

Choice of first-line therapy in metastatic melanoma.

Gibney GT, Atkins MB.

Cancer. 2019 Mar 1;125(5):666-669. doi: 10.1002/cncr.31774. Epub 2019 Jan 29. No abstract available.

PMID:
30695110
6.

Clinical characterization of colitis arising from anti-PD-1 based therapy.

Wang DY, Mooradian MJ, Kim D, Shah NJ, Fenton SE, Conry RM, Mehta R, Silk AW, Zhou A, Compton ML, Al-Rohil RN, Lee S, Voorhees AL, Ha L, McKee S, Norrell JT, Mehnert J, Puzanov I, Sosman JA, Chandra S, Gibney GT, Rapisuwon S, Eroglu Z, Sullivan R, Johnson DB.

Oncoimmunology. 2018 Oct 31;8(1):e1524695. doi: 10.1080/2162402X.2018.1524695. eCollection 2019.

7.

Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series.

Moseley KF, Naidoo J, Bingham CO, Carducci MA, Forde PM, Gibney GT, Lipson EJ, Shah AA, Sharfman WH, Cappelli LC.

J Immunother Cancer. 2018 Oct 11;6(1):104. doi: 10.1186/s40425-018-0417-8.

8.

Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAF V600E-Mutant Melanoma.

Eroglu Z, Chen YA, Gibney GT, Weber JS, Kudchadkar RR, Khushalani NI, Markowitz J, Brohl AS, Tetteh LF, Ramadan H, Arnone G, Li J, Zhao X, Sharma R, Darville LNF, Fang B, Smalley I, Messina JL, Koomen JM, Sondak VK, Smalley KSM.

Clin Cancer Res. 2018 Nov 15;24(22):5516-5524. doi: 10.1158/1078-0432.CCR-18-0565. Epub 2018 Apr 19.

PMID:
29674508
9.

Reply to Improving the survival of patients with American Joint Committee on Cancer stage III and IV melanoma.

Sloot S, Chen YA, Zhao X, Weber JL, Benedict JJ, Mulé JJ, Smalley KS, Weber JS, Zager JS, Forsyth PA, Sondak VK, Gibney GT.

Cancer. 2018 May 15;124(10):2254-2255. doi: 10.1002/cncr.31261. Epub 2018 Mar 15. No abstract available.

10.

Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.

Hallmeyer S, Gonzalez R, Lawson DH, Cranmer LD, Linette GP, Puzanov I, Taback B, Cowey CL, Ribas A, Daniels GA, Moore T, Gibney GT, Tawbi H, Whitman E, Lee G, Mun Y, Liu S, Hamid O.

Melanoma Res. 2017 Dec;27(6):585-590. doi: 10.1097/CMR.0000000000000398.

PMID:
29076950
11.

Resistance mechanisms to genetic suppression of mutant NRAS in melanoma.

Robinson JP, Rebecca VW, Kircher DA, Silvis MR, Smalley I, Gibney GT, Lastwika KJ, Chen G, Davies MA, Grossman D, Smalley KSM, Holmen SL, VanBrocklin MW.

Melanoma Res. 2017 Dec;27(6):545-557. doi: 10.1097/CMR.0000000000000403.

12.

Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies.

Sloot S, Chen YA, Zhao X, Weber JL, Benedict JJ, Mulé JJ, Smalley KS, Weber JS, Zager JS, Forsyth PA, Sondak VK, Gibney GT.

Cancer. 2018 Jan 15;124(2):297-305. doi: 10.1002/cncr.30946. Epub 2017 Oct 12.

13.

Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors.

Creelan BC, Gabrilovich DI, Gray JE, Williams CC, Tanvetyanon T, Haura EB, Weber JS, Gibney GT, Markowitz J, Proksch JW, Reisman SA, McKee MD, Chin MP, Meyer CJ, Antonia SJ.

Onco Targets Ther. 2017 Aug 29;10:4239-4250. doi: 10.2147/OTT.S136992. eCollection 2017.

14.

Clinical Response to Pazopanib in a Patient With KDR-Mutated Metastatic Basal Cell Carcinoma.

Knepper TC, Freeman ML, Gibney GT, McLeod HL, Russell JS.

JAMA Dermatol. 2017 Jun 1;153(6):607-609. doi: 10.1001/jamadermatol.2017.0187. No abstract available.

PMID:
28384659
15.

Resection of Gastrointestinal Metastases in Stage IV Melanoma: Correlation with Outcomes.

Prabhakaran S, Fulp WJ, Gonzalez RJ, Sondak VK, Kudchadkar RR, Gibney GT, Weber JS, Zager JS.

Am Surg. 2016 Nov 1;82(11):1109-1116.

PMID:
28206940
16.

Targeted Therapies in Combination With Immune Therapies for the Treatment of Metastatic Melanoma.

Christiansen SA, Khan S, Gibney GT.

Cancer J. 2017 Jan/Feb;23(1):59-62. doi: 10.1097/PPO.0000000000000245. Review.

PMID:
28114256
17.

Predictive biomarkers for checkpoint inhibitor-based immunotherapy.

Gibney GT, Weiner LM, Atkins MB.

Lancet Oncol. 2016 Dec;17(12):e542-e551. doi: 10.1016/S1470-2045(16)30406-5. Review.

18.

Advances in immunotherapy for melanoma.

Redman JM, Gibney GT, Atkins MB.

BMC Med. 2016 Feb 6;14:20. doi: 10.1186/s12916-016-0571-0. Review.

19.

BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.

Sloot S, Zager JS, Kudchadkar RR, Messina JL, Benedict JJ, Gonzalez RJ, DeConti R, Turner LM, McCardle T, Smalley KS, Weber JS, Sondak VK, Gibney GT.

Melanoma Res. 2016 Feb;26(1):83-7. doi: 10.1097/CMR.0000000000000214.

PMID:
26731560
20.

Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy.

Ahmed KA, Stallworth DG, Kim Y, Johnstone PA, Harrison LB, Caudell JJ, Yu HH, Etame AB, Weber JS, Gibney GT.

Ann Oncol. 2016 Mar;27(3):434-41. doi: 10.1093/annonc/mdv622. Epub 2015 Dec 27.

PMID:
26712903
21.

Immunotherapy or molecularly targeted therapy: what is the best initial treatment for stage IV BRAF-mutant melanoma?

Gibney GT, Atkins MB.

Clin Adv Hematol Oncol. 2015 Jul;13(7):451-8. Review.

PMID:
26353041
22.

Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells.

Fedorenko IV, Abel EV, Koomen JM, Fang B, Wood ER, Chen YA, Fisher KJ, Iyengar S, Dahlman KB, Wargo JA, Flaherty KT, Sosman JA, Sondak VK, Messina JL, Gibney GT, Smalley KS.

Oncogene. 2016 Mar 10;35(10):1225-35. doi: 10.1038/onc.2015.188. Epub 2015 Jun 15.

23.

XL888 Limits Vemurafenib-Induced Proliferative Skin Events by Suppressing Paradoxical MAPK Activation.

Phadke M, Gibney GT, Rich CJ, Fedorenko IV, Chen YA, Kudchadkar RR, Sondak VK, Weber J, Messina JL, Smalley KSM.

J Invest Dermatol. 2015 Oct;135(10):2542-2544. doi: 10.1038/jid.2015.205. Epub 2015 Jun 3. No abstract available.

24.

Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.

Gibney GT, Gauthier G, Ayas C, Galebach P, Wu EQ, Abhyankar S, Reyes C, Guérin A, Yim YM.

Cancer Med. 2015 Aug;4(8):1205-13. doi: 10.1002/cam4.475. Epub 2015 May 20.

25.

Swinging for the Fences: Long-Term Survival With Ipilimumab in Metastatic Melanoma.

Gibney GT, Atkins MB.

J Clin Oncol. 2015 Jun 10;33(17):1873-7. doi: 10.1200/JCO.2014.60.1807. Epub 2015 May 11.

PMID:
25964248
26.

Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype.

Paraiso KH, Das Thakur M, Fang B, Koomen JM, Fedorenko IV, John JK, Tsao H, Flaherty KT, Sondak VK, Messina JL, Pasquale EB, Villagra A, Rao UN, Kirkwood JM, Meier F, Sloot S, Gibney GT, Stuart D, Tawbi H, Smalley KS.

Cancer Discov. 2015 Mar;5(3):264-73. doi: 10.1158/2159-8290.CD-14-0293. Epub 2014 Dec 26.

27.

Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma.

Gibney GT, Kudchadkar RR, DeConti RC, Thebeau MS, Czupryn MP, Tetteh L, Eysmans C, Richards A, Schell MJ, Fisher KJ, Horak CE, Inzunza HD, Yu B, Martinez AJ, Younos I, Weber JS.

Clin Cancer Res. 2015 Feb 15;21(4):712-20. doi: 10.1158/1078-0432.CCR-14-2468. Epub 2014 Dec 18.

28.

LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases.

Ahmed KA, Freilich JM, Sloot S, Figura N, Gibney GT, Weber JS, Sarangkasiri S, Chinnaiyan P, Forsyth PA, Etame AB, Rao NG.

J Neurooncol. 2015 Mar;122(1):121-6. doi: 10.1007/s11060-014-1685-x. Epub 2014 Dec 18.

PMID:
25519302
29.

Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma.

Fedorenko IV, Fang B, Munko AC, Gibney GT, Koomen JM, Smalley KS.

Proteomics. 2015 Jan;15(2-3):327-39. doi: 10.1002/pmic.201400200. Epub 2014 Dec 17.

30.

Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.

Johnson DB, Flaherty KT, Weber JS, Infante JR, Kim KB, Kefford RF, Hamid O, Schuchter L, Cebon J, Sharfman WH, McWilliams RR, Sznol M, Lawrence DP, Gibney GT, Burris HA 3rd, Falchook GS, Algazi A, Lewis K, Long GV, Patel K, Ibrahim N, Sun P, Little S, Cunningham E, Sosman JA, Daud A, Gonzalez R.

J Clin Oncol. 2014 Nov 20;32(33):3697-704. doi: 10.1200/JCO.2014.57.3535. Epub 2014 Oct 6.

31.

Indications and options for systemic therapy in melanoma.

Sondak VK, Gibney GT.

Surg Clin North Am. 2014 Oct;94(5):1049-58, viii. doi: 10.1016/j.suc.2014.07.007. Epub 2014 Aug 6. Review.

PMID:
25245967
32.

Beyond BRAF: where next for melanoma therapy?

Fedorenko IV, Gibney GT, Sondak VK, Smalley KS.

Br J Cancer. 2015 Jan 20;112(2):217-26. doi: 10.1038/bjc.2014.476. Epub 2014 Sep 2. Review.

33.

Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma.

Rebecca VW, Alicea GM, Paraiso KH, Lawrence H, Gibney GT, Smalley KS.

Pigment Cell Melanoma Res. 2014 Nov;27(6):1154-8. doi: 10.1111/pcmr.12303. Epub 2014 Sep 1.

34.

Where to start with systemic melanoma therapy?

Gibney GT, Sondak VK, Smalley KS.

Melanoma Manag. 2014 Aug;1(1):15-18. doi: 10.2217/mmt.14.3. Epub 2014 Sep 5. No abstract available.

35.

Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanoma.

Fedorenko IV, Fang B, Koomen JM, Gibney GT, Smalley KS.

Melanoma Res. 2014 Oct;24(5):448-53. doi: 10.1097/CMR.0000000000000103.

36.

Surgical management of melanoma.

Sondak VK, Gibney GT.

Hematol Oncol Clin North Am. 2014 Jun;28(3):455-70. doi: 10.1016/j.hoc.2014.02.009. Review.

PMID:
24880941
37.

Evaluating melanoma drug response and therapeutic escape with quantitative proteomics.

Rebecca VW, Wood E, Fedorenko IV, Paraiso KH, Haarberg HE, Chen Y, Xiang Y, Sarnaik A, Gibney GT, Sondak VK, Koomen JM, Smalley KS.

Mol Cell Proteomics. 2014 Jul;13(7):1844-54. doi: 10.1074/mcp.M113.037424. Epub 2014 Apr 23.

38.

Setting the bar for adjuvant treatment of melanoma.

Sondak VK, Gibney GT.

Lancet Oncol. 2014 May;15(6):547-8. doi: 10.1016/S1470-2045(14)70177-9. Epub 2014 Apr 15. No abstract available.

39.

p75 neurotrophin receptor cleavage by α- and γ-secretases is required for neurotrophin-mediated proliferation of brain tumor-initiating cells.

Forsyth PA, Krishna N, Lawn S, Valadez JG, Qu X, Fenstermacher DA, Fournier M, Potthast L, Chinnaiyan P, Gibney GT, Zeinieh M, Barker PA, Carter BD, Cooper MK, Kenchappa RS.

J Biol Chem. 2014 Mar 21;289(12):8067-85. doi: 10.1074/jbc.M113.513762. Epub 2014 Feb 11.

40.

Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma.

Rebecca VW, Massaro RR, Fedorenko IV, Sondak VK, Anderson AR, Kim E, Amaravadi RK, Maria-Engler SS, Messina JL, Gibney GT, Kudchadkar RR, Smalley KS.

Pigment Cell Melanoma Res. 2014 May;27(3):465-78. doi: 10.1111/pcmr.12227. Epub 2014 Feb 21.

41.

Long-term effects of BRAF inhibitors in melanoma treatment: friend or foe?

Sloot S, Fedorenko IV, Smalley KS, Gibney GT.

Expert Opin Pharmacother. 2014 Apr;15(5):589-92. doi: 10.1517/14656566.2014.881471. Epub 2014 Jan 24.

PMID:
24456413
42.

Conjunctival melanomas harbor BRAF and NRAS mutations--Letter.

Weber JL, Smalley KS, Sondak VK, Gibney GT.

Clin Cancer Res. 2013 Nov 15;19(22):6329-30. doi: 10.1158/1078-0432.CCR-13-2007. Epub 2013 Oct 28. No abstract available.

43.

Novel treatments for melanoma brain metastases.

Kenchappa RS, Tran N, Rao NG, Smalley KS, Gibney GT, Sondak VK, Forsyth PA.

Cancer Control. 2013 Oct;20(4):298-306. Review.

PMID:
24077406
44.

Recent advances in the treatment of melanoma.

Zager JS, Sarnaik AA, Gibney GT, Kudchadkar RR.

Cancer Control. 2013 Oct;20(4):244-5. No abstract available.

PMID:
24077400
45.

Has targeted therapy for melanoma made chemotherapy obsolete?

Gibney GT, Sondak VK.

Lancet Oncol. 2013 Jul;14(8):676-7. doi: 10.1016/S1470-2045(13)70298-5. No abstract available.

PMID:
23816289
46.

Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma.

Gibney GT, Messina JL, Fedorenko IV, Sondak VK, Smalley KS.

Nat Rev Clin Oncol. 2013 Jul;10(7):390-9. doi: 10.1038/nrclinonc.2013.83. Epub 2013 May 28. Review.

47.

Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.

Gibney GT, Zager JS.

Expert Opin Drug Metab Toxicol. 2013 Jul;9(7):893-9. doi: 10.1517/17425255.2013.794220. Epub 2013 Apr 29. Review.

PMID:
23621583
48.

Meeting report from the Society for Melanoma Research 2012 Congress, Hollywood, California.

Lo RS, Ribas A, Long GV, Ballotti R, Berger M, Willy H, Gibney GT, Bosenberg M, Bernstein E, Villanueva J, Smalley KS.

Pigment Cell Melanoma Res. 2013 Jul;26(4):E1-7. doi: 10.1111/pcmr.12103. Epub 2013 May 13. No abstract available.

PMID:
23551976
49.

An unholy alliance: cooperation between BRAF and NF1 in melanoma development and BRAF inhibitor resistance.

Gibney GT, Smalley KS.

Cancer Discov. 2013 Mar;3(3):260-3. doi: 10.1158/2159-8290.CD-13-0017.

50.

Expanding targeted therapy to NRAS-mutated melanoma.

Gibney GT, Weber JS.

Lancet Oncol. 2013 Mar;14(3):186-8. doi: 10.1016/S1470-2045(13)70054-8. Epub 2013 Feb 13. No abstract available.

PMID:
23414591

Supplemental Content

Loading ...
Support Center